AOP Health Receives Market Authorization for Landiolol in Canada
December 13, 2023 08:55 AM Eastern Standard Time VIENNA–(BUSINESS WIRE)–At the end of November 2023, AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol. The drug is used in intensive care to treat atrial fibrillation and atrial flutter (supraventricular tachycardia) and non-compensatory sinus tachycardia, hence when … Continue reading AOP Health Receives Market Authorization for Landiolol in Canada